Treatment of complications associated with systemic sclerosis

American Journal of Health-System Pharmacy

Volumn 65, Issue 4, 2008, Pages 315-321

  Moore, Stacie C ^a   DeSantis, Evelyn R Hermes ^b,c  

^a ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL   (United States)

^b RWJUH

^c RUTGERS UNIVERSITY   (United States)

Author keywords

Bosentan; Calcium antagonists; Cyclophosphamide; Hypotensive agents; Immunosuppressive agents; Nutrition; Phosphodiesterase inhibitors; Prostacyclin derivatives; Quality of life; Scleroderma

Indexed keywords

ATORVASTATIN; AZATHIOPRINE; BISACODYL; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CYCLOPHOSPHAMIDE; DOCUSATE SODIUM; ERYTHROMYCIN; FASUDIL; HISTAMINE H2 RECEPTOR ANTAGONIST; ILOPROST; LEFLUNOMIDE; LIDOCAINE; METOCLOPRAMIDE; NICOTINE; NIFEDIPINE; OCTREOTIDE; PHENTERMINE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; PREDNISOLONE; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROTON PUMP INHIBITOR; PSEUDOEPHEDRINE; SILDENAFIL; SODIUM DIHYDROGEN PHOSPHATE; TEGASEROD; UNINDEXED DRUG; UNIPROST; ANTIHYPERTENSIVE AGENT; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ABDOMINAL PAIN; ALOPECIA; BLOATING; BLOOD VESSEL INJURY; BRADYCARDIA; CHOLELITHIASIS; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRY EYE; DYSPEPSIA; ECZEMA; FIBROSING ALVEOLITIS; HEADACHE; HEMATURIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTENSION; INFLAMMATION; INJECTION SITE PAIN; INTESTINAL DYSMOTILITY; INTESTINE OBSTRUCTION; KIDNEY DISEASE; LEUKOPENIA; LIVER FUNCTION TEST; LUNG EDEMA; MALABSORPTION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PARENTERAL NUTRITION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; RASH; RAYNAUD PHENOMENON; REVIEW; SCLERODERMA; SIDE EFFECT; SKIN ULCER; SKINFOLD; SYMPTOM; SYSTEMIC SCLEROSIS; XEROSTOMIA; ARTHROPATHY; FEMALE; GASTROINTESTINAL DISEASE; LUNG FIBROSIS; MALE; MUSCLE WEAKNESS; PATHOLOGY; SJOEGREN SYNDROME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; EPOPROSTENOL; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JOINT DISEASES; MALE; MUSCLE WEAKNESS; PHOSPHODIESTERASE INHIBITORS; PULMONARY FIBROSIS; QUALITY OF LIFE; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; SJOGREN'S SYNDROME; SKIN ULCER;

EID: 39549094704     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070024     Document Type: Review

References (51)

1. Charles C, Clements P, Furst DE. Systemic sclerosis: hypothesis-driven treatment strategies. Lancet. 2006; 367:1683-91.
2. Scalapino K, Arkachaisri T, Lucas M et al. Childhood onset systemic sclerosis: classification, clinical and serologic features, and survival in comparison with adult onset disease. J Rheumatol. 2006; 33:1004-13.
3. Gilliland BC. Systemic sclerosis (scleroderma) and related disorders. In: Kasper DL, Braunwald E, Fauci AS et al., eds. Harrison's principles of internal medicine. 16th ed. New York: McGraw-Hill; 2005:1979-90.
4. Nietert PJ, Silverstein MD, Silver RM. Hospital admissions, length of stay, charges, and in-hospital death among patients with systemic sclerosis. J Rheumatol. 2001; 28:2031-7.
5. Derk CT, Arlett CM, Jimenez SA. Morbidity and mortality of patients diagnosed with systemic sclerosis after the age of 75: a nested case-control study. Clin Rheumatol. 2006; 25:831-4.
6. Steen VD. Treatment of systemic sclerosis. Am J Clin Dermatol. 2001; 2:315-25.
7. Merkel PA, Herlyn K, Martin RW et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum. 2002; 46:2410-20.
8. Thompson AE, Shea B, Welch V et al. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum. 2001; 44:1841-7.
9. Milio G, Corrado E, Genova C et al. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol. Rheumatology. 2006; 45:999-1004.
10. Marasini B, Massarotti M, Bottasso B et al. Comparison between iloprost and alprostadil in the treatment of Raynaud's phenomenon. Scand J Rheumatol. 2004; 33:253-6.
11. Boin R, Wigley FM. Understanding, assessing and treating Raynaud's phenomenon. Curr Opin Rheumatol. 2005; 17:752-60.
12. Fries R, Shariat K, Von Wilmowski H et al. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation. 2005; 112:2980-5.
13. Kuwana M, Kaburaki J, Okazaki Y et al. Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis. Arthritis Rheum. 2006; 54:1946-51.
14. Chung L, Fiorentino D. A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis. J Am Acad Dermatol. 2006; 54:880-2.
15. Korn JH, Mayes M, Matucci Cerinic M et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004; 50:3985-93.
16. Gore J, Silver R. Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis. Ann Rheum Dis. 2005; 64:1387. Letter.
17. Tracleer (bosentan) package insert. South San Francisco, CA:Actelion; 2007.
18. Wigley FM, Seibold JR, Wise RA et al. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol. 1992; 19:1407-14.
19. Ozgocmen S, Kaya A, Coskun BK. Topical lidocaine helps reduce pain of digital ulcers in systemic sclerosis (scleroderma). Clin Rheumatol. 2006; 25:378-9.
20. Haustein UF, Haupt B. Drug-induced scleroderma and sclerodermiform conditions. Clin Dermatol. 1998; 16:353-66.
21. Sebastiani M, Giuggioli D, Vesprini E et al. Successful treatment with leflunomide of arthritis in systemic sclerosis patients. Rheumatology. 2006; 45:1175-6. Letter.
22. Kalden JR, Schattenkirchner M, Sorensen H et al. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a 5-year follow-up study. Arthritis Rheum. 2003; 48:1513-20.
23. Pope JE, Bellamy N, Seibold JR et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001; 44: 1351-8.
24. Marie I, Dominique S, Levesque H et al. Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Care Res. 2001; 45:346-54.
25. Bortolotti M. Medical therapy of achalasia: a benefit reserved for few. Digestion. 1999; 60:11-6.
26. Descamps V, Duval X, Crickx B et al. Global improvement of systemic scleroderma under long-term administration of octreotide. Eur J Dermatol. 1999; 9:446-8.
27. Dhir R, Richter JE. Erythomycin in the short- and long-term control of dyspepsia symptoms in patients with gastroparesis. J Clin Gastroenterol. 2004; 38:237-42.
28. Novartis. Zelnorm homepage. www.zelnorm.com (accessed 2007 Dec 20).
29. Reglan (metroclopramide hydrochloride) package insert. Milwaukee: Schwartz Pharm; 2004.
30. Exadaktylos A, Papagrigoriadis S. Chronic constipation - a lethal danger in patients with systemic scleroderma. Eur J Emerg Med. 2001; 8:333-5.
31. Tashkin DP, Elashoff R, Clements PJ et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006; 354:2655-66.
32. Nadashkevich O, Davis P, Fritzler M et al. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol. 2006; 25:205-12.
33. Hoyles RK, Ellis RW, Wellsbury J et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006; 54:3962-70.
34. Williams MH, Das C, Handler CE et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart. 2006; 92:926-32.
35. Cox SR, Walker JG, Coleman M et al. Isolated pulmonary hypertension in scleroderma. Intern Med J. 2005; 35:28-33.
36. Badesch DB, Tapson VF, McGoon MD et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. Ann Intern Med. 2000; 132:425-34.
37. Flolan (epoprostenol sodium) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2006.
38. Oudiz RJ, Schilz RJ, Barst RJ et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest. 2004; 126:420-7.
39. Remodulin (treprostinil sodium) injection package insert. Bloomfield, IL: Baxter Pharmaceutical Solutions LLC; 2006.
40. Ventavix (iloprost) inhalation solution package insert. South San Francisco, CA: CoTherix Inc.; 2005.
41. Olschewski H, Simonneau G, Galie N et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002; 347:322-9.
42. Revatio (sildenafil citrate) package insert. New York: Pfizer Labs; 2005.
43. Galie N, Ghofrani HA, Torbicki A et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005; 353:2148-57. [Erratum, N Engl J Med. 2006; 354:2400-1.]
44. Rosenkranz S, Diet F, Karasch T et al. Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and the Raynaud phenomenon. Ann Intern Med. 2003; 139:871-3.
45. Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002; 346:896-903. [Erratum, N Engl J Med. 2002; 346:1258.]
46. Girgis RE, Mathai SC, Krishnan JA et al. Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. J Heart Lung Transplant. 2005; 24:1626-31.
47. Steen VD. Scleroderma renal crisis. Rheum Dis Clin North Am. 2003; 29:315-33.
48. Rajendran PR, Molitor JA. Resolution of hypertensive encephalopathy and scleroderma renal crisis with an angiotensin receptor blocker. J Clin Rheumatol. 2005; 11:205-8.
49. Avouac J, Sordet C, Depinay C et al. Systemic sclerosis-associated Sjogren's syndrome and relationship to the limited cutaneous subtype: results of a prospective study of siccca syndrome in 133 consecutive patients. Arthritis Rheum. 2006; 54:2243-9.
50. Vivino FB, Al-Hashimi I, Khan Z et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. Arch Intern Med. 1999; 159:174-81.
51. Restasis (cyclosporine ophthalmic emulsion) package insert. Irving, CA: Allergan Inc.; 2004.